A mitoxyperilysis-derived spatial signature predicts immune exclusion and survival in oral squamous cell carcinoma
- 1Liaocheng People's Hospital
Abstract
Immune checkpoint blockade offers limited clinical benefit to patients with oral squamous cell carcinoma (OSCC) harboring immune-excluded microenvironments. The spatial mechanisms maintaining this stromal barricade remain unresolved. Analyzing single-cell and spatial transcriptomics across multiple cohorts, we identified a localized immunosuppressive network driven by mitoxyperilysis--a mitochondria-dependent lytic cell death process. Quantitative spatial mapping revealed that ISG+ PMN-MDSCs and GZMB+ pDCs accumulate at the tumor invasive margin, where they establish a physical and metabolic barrier restricting cytotoxic T-cell infiltration. Computational network ablation confirmed that both subsets are required to maintain this exclusion. We then derived a 5-gene prognostic signature (CTSG, NAMPT, AREG, PLAU, CXCL8) directly from this intercellular communication network. Across independent cohorts, this signature captured an immune desert phenotype and independently predicted patient survival, further improving risk stratification when integrated with standard clinical staging. Our findings define a structural immune evasion axis in OSCC, offering a practical tool to guide combination therapies aimed at remodeling the myeloid-stromal barrier.
Related
- Ferroptosis-related lncRNA signature predicts prognosis and immune microenvironment remodeling in laryngeal squamous cell carcinoma
- An R-loop-related gene signature predicts prognosis and shapes the immune microenvironment in esophageal squamous cell carcinoma.
- Multi-task deep learning integrating pretreatment MRI and whole slide images predicts induction chemotherapy response and survival in locally advanced nasopharyngeal carcinoma
- Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
- An interpretable machine-learning signature predicts early triple-negative breast cancer recurrence but adds no prognostic value beyond clinicopathological factors in external validation
BibTeX
@misc{liu2026mitoxyperilysisderived,
title = {{A mitoxyperilysis-derived spatial signature predicts immune exclusion and survival in oral squamous cell carcinoma}},
author = {J. Liu and D. Zhang and Z. Meng and B. Zou},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.04.26362241},
url = {https://www.medrxiv.org/content/10.64898/2026.09.04.26362241v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - A mitoxyperilysis-derived spatial signature predicts immune exclusion and survival in oral squamous cell carcinoma
AU - J. Liu
AU - D. Zhang
AU - Z. Meng
AU - B. Zou
PY - 2026
DA - 2026/09/04
PB - medRxiv
DO - 10.64898/2026.09.04.26362241
UR - https://www.medrxiv.org/content/10.64898/2026.09.04.26362241v1
AB - Immune checkpoint blockade offers limited clinical benefit to patients with oral squamous cell carcinoma (OSCC) harboring immune-excluded microenvironments. The spatial mechanisms maintaining this stromal barricade remain unresolved. Analyzing single-cell and spatial transcriptomics across multiple cohorts, we identified a localized immunosuppressive network driven by mitoxyperilysis--a mitochondria-dependent lytic cell death process. Quantitative spatial mapping revealed that ISG+ PMN-MDSCs and GZMB+ pDCs accumulate at the tumor invasive margin, where they establish a physical and metabolic barrier restricting cytotoxic T-cell infiltration. Computational network ablation confirmed that both subsets are required to maintain this exclusion. We then derived a 5-gene prognostic signature (CTSG, NAMPT, AREG, PLAU, CXCL8) directly from this intercellular communication network. Across independent cohorts, this signature captured an immune desert phenotype and independently predicted patient survival, further improving risk stratification when integrated with standard clinical staging. Our findings define a structural immune evasion axis in OSCC, offering a practical tool to guide combination therapies aimed at remodeling the myeloid-stromal barrier.
ER -